title: Interleukin-1β, tumour necrosis factor-α and lipopolysaccharide induce C-type natriuretic peptide from canine aortic endothelial cells.
abstract: The N-terminal portion of pro C-type natriuretic peptide (NT-pCNP) has shown promise as a biomarker for sepsis in humans and dogs, however the mechanism of NT-pCNP production in dogs is unknown. Canine aortic endothelial cells were stimulated with lipopolysaccharide, lipoteichoic acid, peptidoglycan, TNF-α, IL-1β, IL-6, IL-10, IL-21, CXCL-8, IFN-γ, VEGF-A or control (PBS), and NT-pCNP production was measured. Lipopolysaccharide, TNF-α, and IL-1β significantly stimulated NT-pCNP production in a dose and time dependent manner; IL-1β resulted in the greatest NT-pCNP concentrations. The other stimulants did not result in significant NT-pCNP production. The addition of serum to the cell culture model did not alter lipopolysaccharide, lipoteichoic acid or peptidoglycan induced NT-pCNP production. These data indicate that lipopolysaccharide, TNF-α and IL-1β regulate CNP production from canine vascular endothelium and of the stimulants tested, IL-1β is the predominant inducing factor. These data provide some initial insight into the mechanisms of CNP regulation in dogs.
authors.affiliation: Comparative Internal Medicine Laboratory, College of Veterinary Medicine, University of Missouri, 900 E. Campus Dr., Columbia, MO 65211, United States.
authors.forename: Kara
authors.initials: K
authors.lastname: Osterbur
authors.forename: Do-Hyeon
authors.initials: DH
authors.lastname: Yu
authors.forename: Amy E
authors.initials: AE
authors.lastname: DeClue
mesh_terms: D000818:Animals; D001011:Aorta / Q000166:cytology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D007371:Interferon-gamma / Q000494:pharmacology; D016753:Interleukin-10 / Q000494:pharmacology; D053583:Interleukin-1beta / Q000494:pharmacology*; D015850:Interleukin-6 / Q000494:pharmacology; D016209:Interleukin-8 / Q000494:pharmacology; D007378:Interleukins / Q000494:pharmacology; D007962:Leukocytes / Q000187:drug effects / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology*; D020098:Natriuretic Peptide, C-Type / Q000096:biosynthesis* / Q000502:physiology; D051197:Toll-Like Receptor 4 / Q000096:biosynthesis; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology; D000098546:Interleukin-21
chemical_list: D053583:Interleukin-1beta; D015850:Interleukin-6; D016209:Interleukin-8; D007378:Interleukins; D008070:Lipopolysaccharides; D051197:Toll-Like Receptor 4; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D020098:Natriuretic Peptide, C-Type; D016753:Interleukin-10; D007371:Interferon-gamma; D000098546:Interleukin-21